Codagenix Inc., a US-based clinical-stage synthetic biology company, announced on Tuesday that it has named Kimber Poffenberger, PhD as its new chief strategy officer.

Dr Poffenberger has more than 20 years of strategic and regulatory leadership experience at pharma and biotech companies. She has held the position of principal consultant at Poffenberger Regulatory Resources, senior vice president, head of Global Regulatory Affairs at Alvotech, vice president and regional US head, Global Regulatory Affairs at GSK Vaccines and as executive director, Global Vaccines Strategy at Merck. Dr Poffenberger has also served in various leadership positions at Intercell, MedImmune, and Iomai Corporation.

J Robert Coleman, PhD, MBA, Codagenix,co-founder and CEO, said, 'We are excited to welcome Kimber to Codagenix. With her distinguished track record of driving global vaccine development and history of successfully leading cross-business strategic teams, she will provide an invaluable perspective to our organisation as we continue to develop our deep clinical pipeline of live attenuated vaccines and cancer virotherapeutics. Kimber brings extensive regulatory and product expertise, which will be critical as we work to bring our medicines to the patients who need them most.'